AbbVie Delivers 400% Returns Beating The S&P 500 by 139%

Ten years ago, AbbVie (NYSE:ABBV | ABBV Price Prediction) was a one-drug story. Humira, the world’s best-selling medicine, threw off the cash that funded everything else. Bears had been warning about its U.S. patent cliff for years, and when biosimilars finally hit in 2023, the drug went into freefall. Humira sales dropped to just $688 million in Q1 2026, down 38.6% year over year, from a peak around $21 billion annually.

The pivot worked. Skyrizi pulled in $4.483 billion in Q1 2026 (up 30.9%) and Rinvoq added $2.119 billion (up 23.3%). The $63 billion Allergan deal in 2020 brought Botox, Juvederm, and a neuroscience franchise that grew 26% last quarter. Full-year 2025 revenue hit $61.16 billion, and management raised 2026 adjusted EPS guidance to $14.08 to $14.28.

Your $1,000 Turned Into $5,000 (If You Held a Decade)

1-Year Return

• Initial Investment: $1,000
• Current Value: $1,189.70
• Total Return: 18.97%
• S&P 500 (same period): $1,281.50 (28.15%)

5-Year Return

• Initial Investment: $1,000
• Current Value: $2,317.40
• Total Return: 131.74%
• Annualized Return: roughly 18%
• S&P 500 (same period): $1,813.80 (81.38%)

10-Year Return

• Initial Investment: $1,000
• Current Value: $5,006.40
• Total Return: 400.64%
• Annualized Return: roughly 17%
• S&P 500 (same period): $3,612.20 (261.22%)

The 10-year number is the headline. AbbVie crushed the index over the long haul while paying out a rising dividend the whole time (the quarterly payout went from $0.57 in 2016 to $1.73 today, and that’s before reinvestment). Holding through 2023, when Humira fears peaked, was the hard part. The 1-year lag versus the S&P reflects a broader market rally that left defensive pharma behind.

The Bull Case, With One Condition

I’d put $1,000 into AbbVie today if I wanted income plus a credible growth engine, and I believed Skyrizi and Rinvoq can carry the franchise until the next wave of pipeline assets, including the non-incretin obesity program ABBV-295, matures. The combined Skyrizi-Rinvoq run rate already exceeds Humira’s peak, and the 3.1% dividend yield with forward P/E near 15 gives me a margin of safety.

I’d avoid it if I’m worried about the next loss-of-exclusivity cycle, which starts hitting Skyrizi and Rinvoq between 2028 and 2033. Heavy IPR&D charges ($5 billion pre-tax in 2025) keep masking GAAP earnings, and a trailing P/E near 104 leaves no room for disappointment.

The bull case looks stronger here. Management has earned the benefit of the doubt by navigating one patent cliff already, and the pipeline looks deep enough to fund the next decade of dividend hikes.